# FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

> **NCT04141995** · PHASE2 · TERMINATED · sponsor: **University of Nebraska** · enrollment: 11 (actual)

## Conditions studied

- Pancreas Cancer
- Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** Digoxin
- **DRUG:** 5Fluorouracil
- **DRUG:** Calcium Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04141995
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-12
- **Primary completion:** 2025-05-13
- **Final completion:** 2025-05-13
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Due to low accrual and futility
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141995, "FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04141995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*